National Guideline Clearinghouse | Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma.

full-text ►

National Guideline Clearinghouse | Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma.



National Institute for Health and Care Excellence (NICE)

Guideline Title

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Jul. 52 p. (Technology appraisal guidance; no. 319).

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.